Related references
Note: Only part of the references are listed.Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics
Timothy A. Yap et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Drug development and clinical trials-the path to an approved cancer drug
Eric H. Rubin et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
A decade of change
John Arrowsmith
NATURE REVIEWS DRUG DISCOVERY (2012)
2011 in reflection
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2012)
Outlook for the next 5 years in drug innovation
Roy Berggren et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Diagnosing the decline in pharmaceutical R&D efficiency
Jack W. Scannell et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Discontinued drugs in 2010: oncology drugs
Robert Williams
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
The problems with today's pharmaceutical business-an outsider's view
Mark Kessel
NATURE BIOTECHNOLOGY (2011)
The productivity crisis in pharmaceutical R&D
Fabio Pammolli et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Envisioning the future of early anticancer drug development
Timothy A. Yap et al.
NATURE REVIEWS CANCER (2010)
Share Paper
